Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer

SIMPLE SUMMARY: In the era of precision medicine, novel targets have emerged on the surface of cancer cells, which have been exploited for the purpose of radioligand therapy. However, there have been variations in the way these receptors are expressed, especially in prostate cancers and neuroendocri...

Descripción completa

Detalles Bibliográficos
Autores principales: Puranik, Ameya D, Dromain, Clarisse, Fleshner, Neil, Sathekge, Mike, Pavel, Marianne, Eberhardt, Nina, Zengerling, Friedemann, Marienfeld, Ralf, Grunert, Michael, Prasad, Vikas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8304541/
https://www.ncbi.nlm.nih.gov/pubmed/34298822
http://dx.doi.org/10.3390/cancers13143607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8304541/
https://www.ncbi.nlm.nih.gov/pubmed/34298822
http://dx.doi.org/10.3390/cancers13143607

Ejemplares similares